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There is no well-stated practical guideline for mechanically ventilated patients with or without acute respiratory distress 
syndrome (ARDS). We generate strong (1) and weak (2) grade of recommendations based on high (A), moderate (B) 
and low (C) grade in the quality of evidence. In patients with ARDS, we recommend low tidal volume ventilation (1A) 
and prone position if it is not contraindicated (1B) to reduce their mortality. However, we did not support high-frequency 
oscillatory ventilation (1B) and inhaled nitric oxide (1A) as a standard treatment. We also suggest high positive end-
expiratory pressure (2B), extracorporeal membrane oxygenation as a rescue therapy (2C), and neuromuscular blockage 
for 48 hours after starting mechanical ventilation (2B). The application of recruitment maneuver may reduce mortality 
(2B), however, the use of systemic steroids cannot reduce mortality (2B). In mechanically ventilated patients, we 
recommend light sedation (1B) and low tidal volume even without ARDS (1B) and suggest lung protective ventilation 
strategy during the operation to lower the incidence of lung complications including ARDS (2B). Early tracheostomy in 
mechanically ventilated patients can be performed only in limited patients (2A). In conclusion, of 12 recommendations, 
nine were in the management of ARDS, and three for mechanically ventilated patients.
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Introduction
Since the first description of acute respiratory distress syn-
drome (ARDS) as a series of 12 patients in 1967 by Ashbaugh 
et al.1, it still remains a major public health problem that incurs 
high health care costs and causes major mortality in the in-
tensive care unit (ICU) despite improvements in outcomes in 
the last two decades. ARDS refers to the occurrence of severe 
hypoxemia that was not corrected by oxygen treatment and is 
characterized by heterogeneous acute lung inflammation with 
increased permeability of the alveolar-capillary membrane, 
resulting in the development of exudate within the alveolar 
space, damage due to activated neutrophils and cytokines, 
and abnormalities of surfactant and the coagulation system2. 
The definition also recently changes as the Berlin criteria3, 
which was modified to the original American-European Con-
sensus Conference definitions4 and novel clinical trial designs 
in ARDS may anticipate a new era of successful therapies. 
Although over the past decades, there has been a remark-
able development in the therapeutic approach and manage-
ment of critically ill patients with ARDS, the mortality of pa-
tients with ARDS is unacceptably high, up to 40%5. In Korea, it 
has been reported that 79 patients with ARDS were admitted 
to the ICUs of 28 university hospitals all over the country with-
in 1 month, July 2009, and 45 of those patients died, resulting 
in a mortality rate of 57%6. Also, until now there is no well-
stated clinical practice guideline for intensivists about ARDS, 
especially focused on the critical care including applying me-
chanical ventilation until now. 
Herein, we report the recommendations and suggestions of 
how to manage mechanically ventilated patients with or with-
out ARDS.
Methods
1. Selection of panel members
The board members of the Korean Society of Critical 
Care Medicine (KSCCM) appointed the editor for the new 
guidelines addressing ARDS management. The panels of the 
guideline committee were recruited from the members of the 
KSCCM and the Korean Academy of Tuberculosis and Lung 
Diseases (KATRD). The KSCCM and KATRD approved all 
panelists, and all of them applied voluntarily to the positions. 
The 16 panelists include intensivists, anesthesiologists, pul-
monologists, pediatricians, and methodologists. All of the pan-
elists were required to disclose any conflicts of interest (COI) 
about the topics. None of the panelists has any COI with the 
related topic.
2. Selection of topics and key questions
The board members of the KSCCM and KATRD agreed 
with the development of guidelines on ARDS management. 
During the 2014 KSCCM conference, we surveyed important 
topics related to ARDS management from the KSCCM mem-
bers. Initially, 20 topics were collected from the survey. Then, 
panel members selected 12 topics, with a consensus. All of 
the panels agreed with the final topics. For each topic, we de-
veloped standardized questions using the PICO (population, 
intervention, comparator, outcome) format.
3. Guideline development
There was no guideline for ARDS management available 
during the beginning of the guideline development meeting, 
and we tried to develop de novo guideline. This guideline is 
based on Korean AGREE II as an assessment tool, which was 
published by the Korean Ministry of Health and Welfare and 
the Korean Academy of Medical Sciences. We ask literature 
search for a specialist. The National Library of Medicine’s 
medical subject headings (MeSH) keyword nomenclature 
was used with PICO. We searched the literature using Med-
line (1948 to July 2014). Searches were limited to literature 
written in English or the Korean language. We searched all of 
the possible investigation methods, including retrospective 
cohort studies and case series. We also searched both original 
investigations and systemic reviews. We assessed the quality 
of systemic reviews and original investigations carefully. 
4. Selection and assessment of study
The keywords and search formula were based on the PICO 
elements of the standardized questions and the study design, 
which is documented in the Korean version (http://www.
ksccm.org or http://www.lungkorea.org). Selection of studies 
was conducted by the specialist of the area. First title screen-
ing was completed, then abstract and full-text screening. If a 
paper was selected for risk of bias assessment, we abstracted 
the data based on the following characteristics: study design, 
participants, intervention, control, outcomes, funding, and 
COI. We assessed the risk of bias using the Cochrane Risk 
of Bias Tool in randomized trials. We also performed meta-
analyses especially in two PICOs, the effect of recruitment 
maneuvers and neuromuscular blockers. However, the results 
of the meta-analysis were the same as previously published 
meta-analyses. 
5. Assessing quality of evidence
The quality of evidence is categorized as high (A level), 
moderate (B level), or low (includes very low) (C level)7,8. The 
rating of the quality of evidence is based on the study design, 
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risk of bias, imprecision, inconsistency, indirectness of results, 
and the likelihood of publication bias.
6. Drafting of recommendations
The strength of recommendation as strong or weak was 
determined based on the value of the study results, wanted 
vs. unwanted effects, and cost effectiveness9,10. The strength 
of recommendation was categorized as strong (grade 1) or 
weak (grade 2). Each author drafted the recommendations 
after the entire panels reviewed the evidence and discussed 
the recommendation. Recommendations were then revised 
several times during meetings in KSCCM conference rooms, 
and through email exchanges that included the entire panel. 
7. Consensus of recommendations
We used a modified Delphi technique11 to achieve a con-
sensus on each recommendation. This technique aims to 
minimize any group interaction bias and to maintain ano-
nymity among respondents. The E-mail was exchanged 
through assistants of KSCCM. Since there was no COI among 
panelists, all panelists voted on their level of agreement with 
each recommendation. If a panel disagreed with the draft of 
a recommendation, the panel suggested a different recom-
mendation. Each panelist provided open-ended feedback 
on each recommendation with suggested wording edits or 
general remarks. To achieve a consensus and to be included 
in the final manuscript, each recommendation had to have an 
at least 50% agreement (strong or weak) with a response rate 
of at least 80% of the total panel members. All recommenda-
tions achieved consensus during the first round. We repeated 
a review by all panel members. 
8. Peer review
External reviewers who were not involved in the develop-
ment of the guideline had reviewed it before it was published. 
These reviewers included different academic society mem-
bers, a methodological expert, and a practicing clinician. The 
final manuscript was reviewed and approved by the Board of 
KSCCM and KATRD. 
Results
The recommendation and level of evidence of 12 topics 
were categorized and summarized in Table 1. The details of 
each topic were as follows.
1. Low tidal volume ventilation
1) Recommendation
- We recommend low tidal volume ventilation can be ap-
plied to patients with ARDS to reduce mortality (grade 1A).
2) Key point
- The tidal volume should be maintained less than 6 mL/kg 
of predicted body weight in patients with ARDS.
- The plateau pressure should be maintained less than 30 
cmH2O in patients with ARDS.
According to analyses of the causes of death in patients with 
ARDS, a majority of patients died of multiple organ dysfunc-






Pros Cons Pros Cons
1 A Low tidal volume ventilation Inhaled nitric oxide - -
B Prone position HFOV Low tidal volume ventilation -
Light sedation Light sedation
C - - - -
2 A - - Early tracheostomy  
(only limited cases)
-
High PEEP (if P/F ≤200) - - -




C ECMO - - -
ARDS: acute respiratory distress syndrome; HFOV: high-frequency oscillatory ventilation; PEEP: positive end-expiratory pressure; ECMO: 
extracorporeal membrane oxygenation.
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tion syndromes (MODS) rather than respiratory failure12, and 
the mortality rate was reported to be significantly higher when 
another organ failure in addition to respiratory insufficiency, 
was involved13. ARDS occurs due to various causes, and many 
kinds of treatments are conducted in individual patients 
based on the cause. Nevertheless, the fact that MODS is the 
predominant cause of death has raised the hypothesis that 
mechanical ventilation, which is essentially and commonly 
administered to all patients with ARDS, can play a major role 
in initiating and propagating a systemic inflammatory reac-
tion. This hypothesis is termed ventilator-induced lung injury 
(VILI), and studies on VILI and its relation to systemic inflam-
matory response syndrome14 and MODS15,16 have been con-
ducted.
The lung of patients with ARDS is characterized by hetero-
geneous inflammation, with congestion and atelectasis of 
dependent alveoli and relatively normal alveoli on the oppos-
ing side2. In this condition, if mechanical ventilation is applied 
with 10–12 mL/kg of tidal volume, which is a conventional 
ventilation strategy, and without positive end-expiratory pres-
sure (PEEP), the physical stretch injury will occur in relatively 
normal alveoli because of overexpansion. Also, damage oc-
curs from shearing forces, in which the repeated collapse 
and reopening of the respiration cycle occurs in basal alveoli 
affected with congestion and atelectasis, and these two inju-
ries are the main mechanisms of VILI17. Barotrauma such as 
pneumothorax, pneumomediastinum, and subcutaneous 
emphysema, and volutrauma such as permeability altera-
tion, pulmonary edema, and diffuse alveolar injury, occur 
via stretch injury. Owing to the shearing force on the site of 
atelectasis, atelectrauma by repeated alveolar collapse and 
reopening occurs. In the whole process, biotrauma due to the 
activation and recruitment of inflammatory cells and media-
tors occurs. These inflammatory mediators are not limited to 
the lung, and they enter into the systemic circulation through 
damaged alveoli-capillary membranes. In infectious lung dis-
eases, bacteria within alveoli can also move into the systemic 
circulation, causing a systemic inflammation similar to sepsis. 
Such systemic inflammation causes MODS, along with organ 
perfusion deterioration due to reduced cardiac output by 
increased pressure within the thorax induced by mechanical 
ventilation, leading to the death of patients15. This is the patho-
logical mechanism of VILI and MODS18. 
Lung protective ventilation (LPV) strategy refers to a me-
chanical ventilation strategy to minimize VILI by adminis-
tering a tidal volume less than the conventional ventilation 
volume and limiting the plateau pressure to reduce injury to 
alveoli by increasing end-expiratory lung volume with PEEP19. 
In a broad sense, prone position ventilation and recruitment 
maneuvers, which minimize VILI by reducing heterogeneity, 
and extracorporeal membrane oxygenation (ECMO), which 
reduces the risk of lung injury from mechanical ventilation 
and a high concentration of oxygen, can also be included in 
LPV.
After detailed mechanisms of VILI had been studied and 
reported, an LPV strategy was conceptualized to prevent VILI, 
and clinical studies were conducted. In 1998, Amato et al.20 
first reported that low tidal volume ventilation had a potential 
clinical effect on patients with ARDS through a randomized 
clinical trial. In 53 patients, the conventional ventilation strat-
egy with a tidal volume of 12 mL/kg, low PEEP, and target-
ing a 35–38 mm Hg partial pressure of carbon dioxide was 
compared with the protective ventilation strategy with a tidal 
volume of 6 mL/kg, high PEEP, and permissive hypercapnia. 
As a result, the protective ventilation group had lower 28-day 
mortality than the conventional ventilation group (38% vs. 
71%), the frequency of barotrauma was low, and weaning rate 
from mechanical ventilation was higher. However, other clini-
cal studies reported at almost the same time showed that low 
tidal volume had no clinical effects on patients with ARDS21-23, 
raising controversy over the clinical effect of low tidal volume.
In this circumstance, the ARDS Network study, the most re-
markable clinical study related to the clinical effect of low tidal 
volume ventilation, was reported24. The study was conducted 
in 10 institutions in the United States for three years on a 
large scale. A tidal volume of 12 or 6 mL/kg of predicted body 
weight was applied to 861 patients, and plateau pressures 
were limited to 50 cmH2O and 30 cmH2O, respectively. The 
low tidal volume ventilation group showed significantly lower 
mortality compared to the conventional ventilation group 
(31% vs. 39.8%, p=0.007). Regarding the indices including 
days without breathing assistance, ventilator-free days, days 
without failure of nonpulmonary organs or systems and blood 
interleukin-6 concentrations, the low tidal volume ventilation 
group showed significant improvement, providing strong 
clinical evidence for the effect of low tidal volume ventilation.
According to the Cochrane review on the clinical trials25,26, 
although there was heterogeneity among studies, it was ana-
lyzed that 28-day and hospital mortalities were significantly 
reduced in the low tidal volume ventilation group. Based on 
the above results of clinical trials and systematic review, the 
Surviving Sepsis Campaign Guideline which was revised in 
2012 recommended low tidal volume ventilation with a high 
level of evidence27. 
Recently, Amato et al.20 reported the result of a multilevel 
mediation analysis about the nine clinical trials of ARDS. Ac-
cording to the result, driving pressure (∆P=VT/CRS; VT, tidal 
volume; CRS, respiratory system compliance) which reflects 
functional lung capacity is more correlated with the mortal-
ity of ARDS patients than tidal volume, plateau pressure, and 
PEEP. However, this was the statistical analysis of previous 
studies, and clinical studies should be performed to confirm 
the clinical effects of ∆P.
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2. High PEEP
1) Recommendation
- We suggest high PEEP can be applied to patients with 
ARDS, who have PaO2/FIO2 ≤200 mm Hg to reduce mortality 
(grade 2B). 
2) Key points
- The application of high PEEP does not increase the risk of 
barotrauma.
- If high PEEP is applied, PaO2/FIO2 at day 1 and three can 
be improved compared to the application of low PEEP group.
PEEP is an easily applicable intervention and an essential 
component of the care of critically ill patients who require ven-
tilator support. The end-expiratory pressure is elevated above 
atmospheric pressure to prevent atelectasis and correct the 
hypoxemia caused by alveolar hypoventilation. Mechanisms 
that PEEP improves through gas exchange and pulmonary 
function are increased functional residual capacity, alveolar 
recruitment, redistribution of extravascular lung water and 
improved ventilation-perfusion matching28. Also, it may pre-
vent repetitive alveolar collapse. High PEEP has been defined 
differently in each study. In ALVEOLI study29, it was based on 
PEEP table, and in EXPRESS study30, PEEP was raised as pla-
teau pressure reached 28–30 cmH2O. It can be expected that it 
may reduce VILI with the above physiological effect. However, 
side effects include an increase in physiologic dead space, de-
creased cardiac output, and increased risk of barotrauma31-33.
A randomized clinical trial that applied high PEEP was con-
ducted with 53 patients with early ARDS20. In the group that 
was exposed to high PEEP and low tidal volume, mortality on 
day 28 (38%) was significantly lower than the conventional 
ventilation group (71%), but there was no significant differ-
ence in survival to hospital discharge. In this study, mortality 
of conventional ventilation group was too high, and the effect 
of high PEEP was observed on day 3. In a second randomized 
study, ICU mortality, hospital mortality, and ventilator-free 
days at day 28 all favored the high PEEP group34.
According to the Cochrane’s review, which meta-analyzed 
seven randomized control trials20,29,30,34-37 conducted from 1998 
to 2009 to compare the effects of the applications of low PEEP 
and high PEEP, there was heterogeneity that five29,30,35-37 out 
of seven included trials had the application of the same tidal 
volume in both high and low PEEP groups, whereas two stud-
ies20,34 had different tidal volumes for the two groups. There-
fore, as a result of analyzing 2,565 patients with ARDS, who 
were administered the same tidal volume with different PEEP, 
high PEEP did not contribute to the reduction of mortality in 
the hospital (relative risk [RR], 0.90; 95% confidence interval 
[CI], 0.81–1.01). In the group with PaO2/FIO2 ≤200 mm Hg, 
high PEEP decreased mortality within the ICU (RR, 0.67; 95% 
CI, 0.48–0.95). The comparison between the two groups on 
barotrauma did not show a significant difference (RR, 0.97; 
95% CI, 0.66–1.42). However, PaO2/FIO2 at days 1 and 3 was 
improved in the high PEEP application group. In a follow-up 
study38 of the two large-scale studies30,36 in 2014, the group in 
which PaO2/FIO2 increased by more than 25 mm Hg within 2 
hours by applying PEEP showing decreased mortality (31% vs. 
51%; odds ratio [OR], 0.8; 95% CI, 0.72–0.89). Also, the reduced 
mortality was observed in patients with increased PaO2/FIO2 
regardless of PEEP among ARDS patients with PaO2/FIO2 
≤150 mm Hg.
If PEEP recruits collapsing alveoli, atelectrauma of alveoli 
can be reduced39 whereas alveolar injury may be increased by 
raising the intensity delivered to alveoli if they are not recruit-
ed40. It is expected that further clinical trials will apply different 
PEEP to patients with enough alveoli to be recruited. Based on 
the above data, high PEEP can be applied to ARDS patients 
with PaO2/FIO2 ≤200 mm Hg.
3. Prone position
1) Recommendation
- We recommend prone position can be applied to patients 
with moderate or above ARDS to reduce mortality if it is not 
contraindicated (grade 1B).
2) Key points
- The prone position should be applied when there is no 
improvement of oxygenation at an early stage of mechanical 
ventilation.
- Prone position is recommended at least for 10 hours.
- Lung protective strategy should also be applied during 
prone positioning.
Based on the theory that the use of the prone position 
would reduce lung injury caused by lung stress and strain 
exerted on the lungs during artificial ventilation in ARDS41-43 
since its first attempt by Bryan in 197444, studies have been 
performed to prove its utility by a number of researchers. In 
a post hoc analysis of Gattinoni et al. in 200145, among PaO2/
FiO2 <88 mm Hg, Simplified Acute Physiology Score II (SAPS 
II) ≥49 and tidal volume >12 mL/kg of predicted body weight 
groups, the group that used the prone position had a lower 
10-day mortality45, and other meta-analyses reported that 
the patients using the prone position in the case of PaO2/FiO2 
<100 mm Hg had lower mortality46-48, but there were a lot of 
controversies over the insistence of the use of the prone posi-
tion can decrease mortality in ARDS. However, a large-scale 
randomized study has recently been conducted by Guerin 
et al.49, reporting that in the PaO2/FiO2 <150 mm Hg group at 
FiO2 >0.6 and PEEP 5 cmH2O, the group that conducted the 
prone position for at least 16 hours per day within 36 hours 
had a statistically significant decreased 28-day mortality rate 
(16.0% prone group vs. 32.8% supine group: hazard ratio [HR], 
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0.39; 95% CI, 0.25–0.63; p<0.001) and 90-day mortality (23.6% 
prone group vs. 41.0% supine group: HR, 0.44; 95% CI, 0.29–
0.67; p<0.001) compared to the group with the supine posi-
tion, despite the mechanical ventilation for 12 or 24 hours49. In 
the meta-analysis conducted after the publication of the large-
scale study by Guerin et al.49, the use of the prone position was 
found to decrease mortality of patients with moderate ARDS50-52. 
However, patient’s severity, low tidal ventilation, time of prone 
position use, and the degree of PEEP were different in each 
study, showing significant heterogeneity41,50,52. When using 
a low tidal volume ventilation concomitantly, the mortality 
was decreased with a statistical significance (RR, 0.66; 95% CI, 
0.5–0.85; p=0.02)49,53-56, but the group without low tidal volume 
ventilation did not show decreased mortality (RR, 1.00; 95% 
CI, 0.88–1.13; p=0.949)56. The time of using the prone position 
showed differences concerning mortality. When the prone 
position was conducted for over 10 hours, a clearly decreased 
mortality was found (OR, 0.62; 95% CI, 0.48–0.79; p<0.001), 
and the randomized study by Taccone et al.53 and Mancebo 
et al.54, as well as meta-study by Hu et al.51 and Beitler et al.56, 
reported that the decrease in mortality was evident when the 
prone position was conducted for 12 hours or more. In the 
large-scale randomized study conducted by Guerin et al.49, the 
prone position was performed for more than 19 hours49,51,53-55. 
However, when the prone position period was less than 12 
hours, there was no decrease in mortality (OR, 1.04; 95% CI, 
0.80–1.36; p=0.757). No reduction in mortality was shown 
when analyzing patients with acute lung injury or mild ARDS 
(OR, 1.02; 95% CI, 0.76–1.36; p=0.920)50. Although there were 
not many studies on the degree of PEEP, the meta-analysis 
published by Hu et al.51 reported that the group maintaining 
high PEEP ≥10 cmH2O–13 cmH2O showed a lower 60-day 
mortality (RR, 0.82; 95% CI, 0.68–0.99; p=0.04) and 90-day 
mortality (RR, 0.57; 95% CI, 0.43–0.75; p<0.0001), compared 
to the group maintaining PEEP <10 cmH2O when conducting 
prone position.
In randomized clinical trials and meta-analyses, the use of 
the prone position was reported to improve hypoxemia. Com-
pared to the group using the supine position, the prone posi-
tion group showed an increase of PaO2/FiO2 by 25%–36% for 
the first 3 days44,45,52, which contributed to the improvement of 
perfusion imbalance by reducing the collapse of the depen-
dent portion of the lung, as well as edema41,57,58.
In three randomized clinical trials, there was a study on 
mechanical ventilation period53,55,59, showing no difference in 
the mechanical ventilation period between the prone posi-
tion and supine position patient groups. In two randomized 
clinical trials, the result of ICU length of stay showed no differ-
ence between the prone position and supine position patient 
groups53,55. 
In the study of Guerin et al.49, patients were ventilated while 
in the prone position for more than 19 hours. A meta-study by 
Lee et al.50 reported that the decrease in mortality in the prone 
position for more than 10 hours was statistically significant, 
and randomized study of Taccone et al.53 and Mancebo et 
al.54, and meta-study of Hu et al.51 and Beitler et al.56 showed 
that the decrease in mortality was clear when using the prone 
position for more than 12 hours49,51,53-55. However, if the dura-
tion of the prone position is less than 10 hours, there was no 
decrease in mortality (OR, 1.04; 95% CI, 0.80–1.36; p=0.757)50. 
Studies49,50,53-56 showed different indications regarding the dis-
continuation time when conducted in the prone position. In 
Guerin et al.49, the prone position was discontinued when (1) 
there was improvement of hypoxemia (PaO2/FIO2 ≥150 mm 
Hg with PEEP ≤10 cmH2O and FIO2 ≤0.6), (2) when PaO2/FiO2 
deteriorated by 20% or more compared to the supine position, 
and (3) when complications occurred due to the prone posi-
tion. It is thought that further studies on daily use time and 
total treatment period for the prone position will be needed.
The complications related to prone position include extuba-
tion, endotracheal tube obstruction, selective main bronchus 
intubation, pneumothorax, cardiac arrest, arrhythmia, loss of 
venous or arterial access, increased pressure ulcers, pneumo-
nia related to mechanical ventilation, and increased use of 
sedatives41,54,56. Rarely, there was no statistical difference of op-
tic nerve injury, retinal scarring, cardiac arrest, loss of arterial 
access, and pneumonia related to mechanical ventilation be-
tween prone and supine position patient groups50. There are 
contraindications for the use of prone position41,49; (1) patients 
with intracranial pressure >30 mm Hg or cerebral perfusion 
pressure <60 mm Hg, (2) patients with massive hemoptysis, 
(3) patients who have received tracheal surgery or sternotomy 
within 15 days, (4) patients with head injuries within 15 days, 
(5) patients who had deep vein thrombosis within 15 days, (6) 
patients who have received an inserted cardiac pacemaker 
within 15 days, (7) patients with spine, femur, or pelvis frac-
ture, (8) patients with mean arterial pressure ≥65 mm Hg, (9) 
pregnant women, (10) patients with thoracic duct in precor-
dial region, and (11) patients with abdominal open wound. In 
the randomized study conducted by Guerin et al.49, patients 
with ECMO were subjects to be excluded, but in recent stud-
ies, the use of prone position after performing EMCO without 
complications was reported. Especially, regarding the loss of 
ECMO was difficult in patients who received venous ECMO, 
some cases reported a successful loss of ECMO using the 
prone position60-63.
4. Extracorporeal membrane oxygenation
1) Recommendation
- We suggest ECMO as a rescue therapy in patients with 
ARDS without improvement of hypoxia by LPV strategy (grade 
2C).
Since the first application of ECMO in patients with severe 
hypoxia and respiratory failure in 197264, two randomized 
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clinical trials65,66 have been performed, both group of ECMO 
and control which showed only a high level of mortality and 
failed to show any difference in mortality. However, the results 
of a number of prospective observational studies published 
after the development of ECMO at the end of the 90s67,68 
showed the survival rate of ARDS applied by ECMO contin-
ued to increase, and in patients with H1N1 influenza-ARDS 
receiving ECMO, particularly, a high survival rate was found 
(RR, 0.45; 95% CI, 0.26–0.79; p=0.008)67. On the other hand, in 
the third randomized clinical trial conducted in 2009, ECMO 
showed a statistically significant difference in death or disabil-
ity at 6 months in patients with adult influenza-ARDS patients 
with severe respiratory failure (RR, 0.69; 95% CI, 0.05–0.97; 
p=0.03), but did not show a significant decrease in mortality 
regarding the mortality itself at 6 month or before discharge 
(RR, 0.73; 95% CI, 0.52–1.03; p=0.07), along with many limi-
tations in methodology of study69,70. In addition, a recently 
conducted meta-analysis mentioned that the effect of the ap-
plication of ECMO in patients with severe ARDS cannot be 
concluded in the current situation because of the effect on the 
improvement of mortality was not statistically significant (OR, 
0.71; 95% CI, 0.34–1.4; p=0.358)71. Therefore, the application of 
ECMO in patients with ARDS must be limitedly or selectively 
performed, especially for severe ARDS patients, after consid-
ering financial and ethical issues thoroughly until the ongoing 
large-scale randomized study result19 comes out. Regarding 
this, a cohort analysis68 in 2013 reported that prognosis would 
be bad if age, lactate level, and plateau pressure before the ap-
plication of ECMO were high. A domestic retrospective obser-
vational study72 has shown that survival rate tended to be high 
if relatively early ECMO is conducted in young patients.
In patients with ARDS, among mechanical ventilation ap-
plied by low tidal volume and enough PEEP, ECMO may 
be tried as a salvage therapy if low tidal volume ventilation 
cannot be maintained because of persistent hypoxemia or in-
tolerable hypercapnia73. However, the cause of ARDS should 
be reversible, or lung transplantation should be possible, and 
especially the period for the application of mechanical ventila-
tion should be at least within seven days before considering 
ECMO for ARDS. Also, patients must not be in irreversible 
multi-organ failure or end stage cancers at the time of receiv-
ing ECMO. Patients should also not be in the condition of 
irreversible central nervous disorders. Particularly, there may 
be limits of use in patients with current acute bleeding or a 
high bleeding tendency because the use of a lot of anticoagu-
lants will be needed during ECMO70. Regarding appropriate 
patient selection, the application of Respiratory ECMO Sur-
vival Prediction Score (RESP-score) which is derived from the 
recent the Extracorporeal Life Support Organization (ELSO) 
data analysis may be considered, but it is not possible to be 
considered as an absolute indication74. Urgent studies should 
be conducted to evaluate the possibilities of domestic applica-
tion of such prognosis precursors.
The complications related to ECMO can be largely divided 
into the complications related to patients and related to the 
device. According to the data published by ELSO70, complica-
tions related to patients were reported to be complications 
related to infection identified for culture (18%), followed by 
bleeding in the catheterization site (15%), and bleeding in the 
operation site (14%). Regarding the complications related to 
the device, the blood coagulation in oxygenation device was 
reported to be most common with 20%. To prevent such com-
plications, multi-disciplinary team related to ECMO should 
be made to conduct continuous education and simulation 
programs. It is also important to monitor patients, the device, 
and the whole team constantly. As the long-term prognosis of 
patients who receive ECMO is not known yet, further studies 
about this are also needed.
Currently, the technology of ECMO is developing very 
quickly, and the new membrane oxygenator and catheter, 
which are not available in Korea, are being developed. Also, 
the need for experienced centers in which ECMO can be con-
ducted skillfully is constantly rising. Although it is true that the 
application of ECMO is explosively increased through the ex-
perience in ARDS accompanied to H1N1 influenza, there are 
still some problems, including selecting adequately applicable 
patient groups, optimal catheter composition, and method, 
appropriate mechanical ventilation and cost-effectiveness 
during ECMO. Therefore, until results of some well-planned 
randomized studies come out, the application of ECMO in 
patients with ARDS may be conducted relatively early only if 
there is no improvement after applying known LPV strategies 




- We suggest recruitment maneuver can be applied to pa-
tients with ARDS to reduce mortality (grade 2B). 
2) Key points
- Recruitment maneuver has an effect on improving hypox-
ia, without increasing the risk of barotrauma.
Recruit maneuver (RM) can prevent repeated opening and 
closing by opening the collapsed alveoli. Also, if the collapsed 
alveoli are opened by RM, the lung volume with overall venti-
lation will be increased to distribute the same amount of tidal 
volume to more alveoli, resulting in the reduction of alveolar 
overdistention in patients with ARDS as well. There are some 
methods of RM, but the one that uses airway pressure is most 
commonly used. Usually, RM is conducted so that pressure is 
applied maintain airway pressure at 35–45 cmH2O for 30–40 
seconds. In the past, the method to reach the target pressure 
by exerting a large volume once in the middle of respiration 
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was used75. Recently, the method where the target pressure is 
obtained by gradually increasing PEEP and decreasing pres-
sure support is also used76.
The existing RM studies showed a significant improvement 
of hypoxia after RM77,78. According to a recent meta-analysis79 
and the results of our analysis on RM studies, a statistically 
significant decrease in mortality was observed in RM group 
compared to the control group. However, because each study 
is different with the risk of bias, and there is a possibility that 
other ventilator interventions conducted along with RM af-
fected the outcome, it must be careful to interpret the result. 
There was no significant difference of barotrauma between 
RM and control groups77-79.
Low blood pressure often occurs during RM, but most cases 
are recovered after RM. It is thought that it is because the lung 
is distended to reduce preload and increase afterload of the 
right ventricle in RM. A temporary hypoxia may occur during 
RM because alveoli that are already opened are overexpanded 
by high airway pressure to press adjacent blood vessels, re-
ducing the perfusion of alveoli with good ventilation. However, 
most instances of hypoxia will be improved when the airway 
pressure is reduced after RM. Furthermore, if collapsed alveoli 
are opened because of successful RM, overall hypoxia will be 
improved, and hypoxic vasoconstriction will also be reduced 
to decrease the afterload of the right ventricle. Due to high 
airway pressure in RM, barotrauma is concerned. Fortunately, 
according to existing prospective studies, the occurrence of 
pneumothorax is reported to be very small77,78.
The groups expected to have good RM will now be dis-
cussed. Patients with ARDS in the early “exudative” phase are 
more likely to react with RM than the ones in the late “fibrotic” 
phase80. Extrapulmonary ARDS is more likely to react with 
RM than pulmonary ARDS81,82. The case in which ARDS is dif-
fused is more likely to succeed in recruitment than the locally 
diffused case, and the effect of RM drops when baseline PEEP 
before RM is high82. Severe ARDS rather than moderate ARDS 
is more likely to be recruited.
6. Systemic steroids
1) Recommendation
- The use of systemic steroids cannot reduce mortality in 
patients with ARDS (grade 2B).
2) Key points
- In the case of a low dose of systemic steroid is used in the 
early stage, it may improve hypoxemia and reduce the period 
of mechanical ventilation, the length of ICU stay, and mortal-
ity.
Because systemic steroids have strong anti-inflammatory 
and anti-fibrotic effects in patients with ARDS, it has been 
considered an effective treatment. Based on this idea83-85, sev-
en randomized control trials have been conducted from 1985 
to 200786-92. However, these trials reported different results 
regarding the effect of the use of steroids for the reduction of 
mortality in patients with ARDS. In 1998, Meduri et al.89 re-
ported that mortality was decreased as a result of administer-
ing methylprednisolone 2 mg/kg in patients with unresolved 
ARDS within seven days after artificial intubation for 32 days 
(12.5% for corticosteroids vs. 62.5% for placebo, p=0.04). Based 
on this, ARDS Network conducted the Late Steroid Rescue 
Study (LaSRS)90. In this study, mortality was compared after 
administering methylprednisolone 2 mg/kg in patients with 
ARDS, which passed 7 days or more after artificial intubation 
for 25 days. Here, the 60-day mortality (29.2% for cortico-
steroids vs. 28.6% for placebo, p=1.0) and 180-day mortality 
(31.5% for corticosteroids vs. 31.9% for placebo, p=1.0) could 
not be reduced, but the 60-day mortality of patients whose ar-
tificial intubation passed 14 days was reported to be increased 
(35% for corticosteroids vs. 8% for placebo, p=0.02). A meta-
analysis of randomized and cohort studies also showed con-
flict results93-99. There were studies that supported that steroids 
did not affect the improvement of mortality94,95 whereas other 
studies suggested that the use of low dose of steroids (≤meth-
ylprednisolone 2 mg/kg) within 14 days after the occurrence 
of ARDS might show improvement on short-term mortal-
ity96,99. However, because the studies included in the analysis 
contain cases with different administration doses of steroids, 
the severity of disease, the cause of lung injury, starting a pe-
riod of steroid administration, and application method of the 
mechanical ventilation, which make it difficult to conclude the 
effect of the administration of steroids.
In the LaSRS, it was reported that the use of steroids (meth-
ylprednisolone 2 mg/kg) in patients with ARDS within seven 
days or more of the disease period would improve hypox-
emia90. Further, Meduri et al.89 (methylprednisolone 2 mg/kg) 
in 1998 reported that the use of steroids improved hypoxemia 
in patients with ARDS (PaO2/FiO2 of 262 for corticosteroids vs. 
148 for placebo; p<0.001), and Confalonieri et al.100 reported 
that PaO2/FiO2 showed statistically significant improvement 
in the group that was administered steroids (hydrocortisone 
200 mg) (p=0.0007). In the same study, the use of steroids in 
patients with ARDS with 7 days or more of a disease period 
improved respiratory elastance and blood pressure and re-
duced the days of application of a respirator for the first 28 
days, shock continuation days, and ICU hospitalization pe-
riod90. In Meduri et al.91 and Annane et al.92, there were reports 
that it reduced the days of application of mechanical ventila-
tor90-92 and ICU hospitalization period91.
Weigelt et al.86, who used a high dose of steroids (methyl-
prednisolone 30 mg/kg every 6 hours for 48 hours)86 reported 
that infection rate increased in the group using steroids, and a 
systemic review of Lamontagne et al.97 also reported that the 
risk of infection would increase when using a high dose of ste-
roids (RR, 1.77; 95% CI, 1.23–2.54). However, Annane et al.92 
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(hydrocortisone 50 mg every 6 hours) or Meduri et al.91 (meth-
ylprednisolone, 2 mg/kg), and the LaSRS reported that the 
use of low-dose steroid therapy would not increase infection 
rate89,91,92. However, because the definitions of the secondary 
infection related to steroids were different each other, screen-
ings were not properly conducted, and the number of patients 
was small, it is still controversial whether the secondary infec-
tion rate will be increased if steroids are used in patients with 
ARDS.
When steroids are used in patients with ARDS, steroid-
related neuromyopathy makes the body unable to move. 
When a neuromuscular blocking agent is used, the action of 
a glucocorticoid will be reinforced. If sepsis is involved, it was 
considered to occur as it promoted degradation of myopro-
tein. In the LaSRS, neuromyopathy occurred in nine patients, 
and all of them occurred in the group using steroids (p=0.001). 
However, other studies reported that the use of steroids did 
not increase myopathy with statistical significance (Meduri et 
al.91: 6.4% for corticosteroids vs. 3.6% for placebo, p=1.0; Con-
falonieri et al.100: 0% for corticosteroids vs. 13% for placebo, 
p=0.001)91,100. Since there is a controversy over steroid-related 
myopathy because of insufficient studies on it, further studies 
will be needed. Complications including gastrointestinal tract 
bleeding, hyperglycemia, other major organ failures (heart, 
kidney, and liver), arrhythmia, pneumothorax, and psychiatric 
disorders were reported, but their incidence did not show a 
statistically significant increase in patients with the steroid 
administration group90-92,100. Besides, there was a report that 
patients in the steroid administration group had a higher fre-




- We suggest using neuromuscular blockade for 48 hours 
after starting mechanical ventilation in patients with ARDS 
(grade 2B). 
2) Key points
- The use of neuromuscular blockage in patients with ARDS 
has an effect on improvement of hypoxemia for first 48 hours. 
- The use of neuromuscular blockage can reduce barotrau-
ma such as pneumothorax in patients with ARDS.
Neuromuscular blockage can maintain transpulmonary 
pressure appropriately and reduce lung injury related to me-
chanical ventilation by reducing asynchrony of ventilator and 
patients’ respiration in ARDS101. Including prospective studies 
related to neuromuscular blockage102,103 and a retrospective 
study related to acute respiratory failure104, meta-analyses 
showed the effect of neuromuscular blockage on mortality 
reduction with great effect (OR, 0.78; 95% CI, 0.39–0.90). Ad-
ditionally, an observational study showed that the early use of 
neuromuscular blockage had an effect on reducing mortality 
in severe sepsis caused by the respiratory system104. However, 
to confirm the daily use of neuromuscular blockage in ARDS, 
more studies including larger scaled clinical trials are still re-
quired105. 
Neuromuscular blockage can reduce elastance of the tho-
rax to relieve ventilation/perfusion imbalance in ARDS. In a 
retrospective study, the use of neuromuscular blockage for 48 
hours had an effect on improving hypoxemia up to day 5101. In 
a meta-analysis, however, the effect that hypoxemia was sig-
nificantly improved at 48 hours after beginning the treatment 
with neuromuscular blockage when compared to the control 
group106. Although the mechanism improving hypoxemia is 
not clear, it is thought that synchrony between patient respira-
tion and mechanical ventilation will be improved to change 
lung compliance and gas exchange for the better. Also, the 
mechanism is thought to reduce barotrauma and atelectasis 
in expiration by controlling inhaled air volume and pressure 
in lung inflammatory reaction, consequently resulting in the 
reduction of lung and systemic inflammations107. Although it 
can be expected that the duration of mechanical ventilation 
will be increased because of weakened neural muscles due 
to neuromuscular blockage, the meta-analysis showed that it 
was not different from the control group. However, successful 
ventilator-free days were longer in the group using neuromus-
cular blockage by comparing the risk of death and period of 
mechanical ventilation106.
Although neuromuscular blockage is known to be related 
to weakness generated in ICU, the weakness in patients with 
ARDS who used it for 48 hours did not increase significantly 
when compared to the control group in the meta-analysis106. 
The method to measure weakening of neural muscles after us-
ing neuromuscular blockage is possible to decrease sensitivity 
and specificity of diagnosis based on quadriplegia that may be 
clinically measured101,102. However, a recent study evaluated 
the weakening of muscles based on Medical Research Coun-
cil scores108, and if the weakening of muscles is not discovered 
is considered, it can be thought that the use of neuromuscular 
blockage in ARDS for less than 48 hours did not significantly 
increase weakening of neural muscles. This is different from 
the long-term muscle weakening that occurred after using 
neuromuscular relaxant in patients with asthma and sepsis in 
the past109,110. 
When the neuromuscular blockage is used in patients with 
ARDS for 48 hours, barotrauma such as pneumothorax was 
significantly reduced compared to control group. In three 
retrospective studies, comparative risk (RR, 0.43; 95% CI, 0.20–
0.90; p=0.02; I2=0), indicated a lesser degree of barotrauma 
when compared to the control group106.
If a patient has a renal or liver function disorder as well as 
cardiovascular problems, the careful selection of neuromus-
cular blockage will be needed. Patients with normal renal and 
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liver functions prefer pancuronium, and the ones with renal 
or liver function disorders prefer atracurium or cisatracurium. 
In cases of the cardiovascular problem, vecuronium is known 
to be hemodynamically stable with the least amount of side 
effects111,112.
8. High-frequency oscillatory ventilation 
1) Recommendation
- The use of high-frequency oscillatory ventilation (HFOV) 
should not be recommended as a standard treatment method 
in adult patients with ARDS (grade 1B).
2) Key points
- HFOV does not improve survival in patients with ARDS.
- HFOV may cause side effects such as barotrauma or low 
blood pressure.
As a result of meta-analysis, the application of HFOV in pa-
tients with ARDS had no difference, compared with conven-
tional mechanical ventilation, in the 30-day or overall hospital 
mortality61,113,114. Rather, based on the result of studies that 
were terminated because of significantly increased the mortal-
ity of patients with ARDS (RR, 1.33; 95% CI, 1.09–1.62; p<0.01), 
the regular application of HFOV in patients with ARDS is not 
recommended115,116. When applying a LPV strategy, particular-
ly, it seems there is no additional benefit of HFOV. In a meta-
analysis114 and randomized control trials115-118, there was no 
difference in the duration of mechanical ventilation between 
HFOV and conventional mechanical ventilation. Because 
HFOV maintains very small tidal volume and high mean air-
way pressure, the improvement of oxygenation can be expect-
ed. In a meta-analysis excluding children113, the improvement 
effect of oxygenation (PaO2/FIO2) by HFOV continued from 
the first 24 hours to three days, but it was not identified in the 
case of including children61. Therefore, it is hard to conclude 
that HFOV has an effect on the improvement of oxygenation. 
Also, even with the improvement of oxygenation, the causes 
of lung injury or ARDS will not be improved, and most pa-
tients with ARDS died of multiple organ failure119. Therefore, 
temporary improvement of oxygenation seems difficult to be 
connected to the improvement of survival rate120.
In a meta-analysis, the application of HFOV tended to 
increase hemodynamic instability such as barotrauma and 
low blood pressure, but it was not statistically significant. 
Such side effects showed that higher mean airway pressure 
in patients who receive HFOV up to 3 days113, which resulted 
in decreased venous return by intrathoracic pressure and in-
creased right ventricular afterload121,122.
9. Inhaled nitric oxide in adult and child patients with 
ARDS
1) Recommendation
- The use of inhaled nitric oxide (iNO) should not be recom-
mended as a standard treatment method in adult and child 
patients with ARDS (grade 1A).
2) Key points
- The use of iNO in patients with ARDS may increase the 
risk of renal injury in adults.
As a result of meta-analyses, the use of iNO in patients with 
ARDS showed no significant reduction in mortality when 
compared to the control group, regardless of the severity of 
hypoxemia123,124. The iNO could be considered when patients 
appear to be at great risk of imminent death from hypoxemia 
despite all other treatments. In meta-analyses, the use of iNO 
showed insignificant beneficial effects on the duration of me-
chanical ventilation and length of stay in the ICU compared 
to the control group123,124. As a result of meta-analyses, the 
improved oxygenation (PaO2/FIO2) was observed in the first 
24 hours123,125,126. Although iNO is supposed to improve oxy-
genation by reducing ventilation-perfusion mismatch at first, 
it will induce vasodilatation of poorly ventilated areas, increas-
ing ventilation-perfusion mismatch127. Improved oxygenation 
is not associated with increased survival rate because the 
temporary improvement of oxygenation does not indicate 
improved lung function, reduction of lung injury, or resolution 
of the underlying cause of ARDS including coexisting multi-
organ damage128. 
With the use of iNO, the difference of pulmonary arterial 
pressure was initially significant at the first day but no longer 
present on day 2 to 4123. The use of iNO increased the risk of 
renal injury among adult patients with ARDS123,129. Nitric ox-
ide (NO) is known as an important regulator renal vascular 
tone and a modulator of glomerular function. Therefore, the 
changes in NO production could cause acute renal injury by 
altering the function of mitochondria, various enzymes, and 
DNA. Despite insufficient randomized controlled trials or 
meta-analyses, the combination therapies with prone posi-
tioning or HFOV may help in selected groups of patients or as 
a salvage therapy because they can enhance the effect of iNO 
than monotherapy alone128.
10. The prevention of ARDS in mechanically ventilated 
patients
1) Recommendation
- We recommend low tidal volume ventilation can be ap-
plied in patients who require mechanical ventilation for dis-
eases other than ARDS (grade 1B). To lower the incidence of 
pulmonary complications including ARDS in intraoperative 
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patients, LPV strategy may be applied during the operation 
(grade 2B).
In mechanically ventilated patients without ARDS, the 
application of low tidal volume can decrease the incidence 
of ARDS130. In the only randomized control study, the occur-
rence of ARDS increased in the patient group with a tidal vol-
ume of 10 mL/kg rather than the group with tidal volume of 6 
mL/kg (predicted body weight) among ICU patients requiring 
mechanical ventilation for 72 hours or more (RR, 5.1; 95% CI, 
1.2–22.6; p=0.01)130. Moreover, the patient group with high 
tidal volume had an increased incidence of ARDS, and this 
study was terminated earlier. The studies on the prevention of 
ARDS are mostly observational cohort studies131-135, and meta-
analysis is difficult to be conducted because of heterogeneity 
between studies. According to a systematic review conducted 
recently, however, in one randomized control study and most 
observational studies, the relationship between high tidal 
volume and the occurrence of ARDS136 was suggested. How-
ever, several observational studies showed that fluid imbal-
ance135,137 and transfusion131,134,135,137-139 may also contribute to 
the occurrence of ARDS.
In patients requiring endotracheal intubation for general 
anesthesia and mechanical ventilation during surgery, the 
application of low tidal volume can lower postoperative pul-
monary complications140,141. The studies on mechanical venti-
lation during operation are limited in number, and the studies 
conducted so far are the results of observational studies142,143 
which dealt with the change in inflammatory cytokines 
considered to mediate the occurrence of ARDS rather than 
directly identifying the ARDS144-146. Both observational cohort 
studies which were conducted in patients without acute lung 
injury under non-thoracic surgery142 and a case-control study 
conducted in patients under various surgeries including lung 
surgery143 did not reveal the relationship between tidal volume 
and ARDS. However, the difference of tidal volume between 
patient groups might not be wide enough to make an ARDS. 
The tidal volume as the use of high tidal volume may be re-
duced because those studies were conducted after the study 
that the use of low tidal volume brought the reduction of mor-
tality in ARDS. Also, there is an opinion that the use of PEEP 
was not generalized in the group applied by low tidal volume, 
so the occurrence of atelectasis could not be prevented142,147. 
However, in a recent study148, the application of high PEEP 
increased the occurrence of hypotension during surgery, 
compared to low PEEP. Therefore, it is important to apply ap-
propriate PEEP during surgery, but it is difficult to suggest its 
accurate levels. In the observational cohort study conducted 
in 1,091 patients who received a pneumonectomy within a 
10-year period, the reduction of the occurrence of ARDS was 
found when a LPV strategy was performed during one-lung 
ventilation (adjusted OR, 0.34; 95% CI, 0.23–0.75; p=0.0002)141. 
There was a randomized control study conducted in patients 
who received a pneumonectomy, which showed both PaO2/
FiO2 <300 mm Hg or the occurrence of new lung lesions were 
decreased in the group of lung protective strategy whereas 
the occurrence of ARDS did not show a statistical difference 
because of its small number149. A recent randomized control 
study140 conducted in patients who received abdominal sur-
gery showed a similar result; the LPV strategy including low 
tidal volume and moderate PEEP lowered the occurrence of 
respiratory complications for 7 days after the abdominal oper-
ation, compared to non-lung protective strategy (adjusted RR, 
0.49; 95% CI, 0.32–0.74; p<0.001). However, both the groups 
had very small number of occurrence of ARDS, and there was 
no statistical significance between the two groups (adjusted 
RR, 0.21; 95% CI, 0.02–1.71; p=0.14). In this study, the fact that 
pneumonia and sepsis occurrence, and the main risk factors 
for ARDS, were decreased in the LPV strategy group suggests 
the possibility that the use of LPV strategy during the opera-
tion under general anesthesia can reduce the occurrence of 
ARDS.
11. Sedation, analgesia, and delirium in mechanically 
ventilated patients
1) Recommendation
- We recommend light sedation should be conducted in 
critically ill patients who receive mechanical ventilation in-
cluding ARDS (grade 1B).
2) Key points
- We suggest pain should regularly be evaluated in critically 
ill patients who receive mechanical ventilation in ICU.
- It is required to have a proper prevention for the occur-
rence of delirium caused by the absence of appropriate anal-
gesia and sedation or other physical diseases.
Light sedation should be conducted in the mechanically 
ventilated patients including ARDS (1B). It is known that 
waking patients up every day or using light sedation will have 
clinically better results150,151. As a method to evaluate sedation, 
it is recommended to use Richmond Agitation-Sedation Scale 
(RASS) or Sedation-Agitation Scale (SAS)152,153. A variety of 
sedatives has been used to induce adequate sedation in pa-
tients. Recently, because using non-benzodiazepine sedatives 
(propofol and dexmedetomidine) is known to cause better 
clinical outcomes than using benzodiazepines (midazolam 
and diazepam) in mechanically ventilated patients includ-
ing ARDS, it is recommended to conduct sedation with non-
benzodiazepine drugs (2B)154. 
It is recommended to evaluate the pain during ICU admis-
sion regularly for mechanically ventilated patients including 
ARDS155. Those who can communicate without endotracheal 
intubation can directly describe their pain by conducting 
visual analog scale or numeric rating scale, etc. However, 
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patients who cannot directly express their pain because of 
endotracheal intubation or unconsciousness should evaluate 
the pain through behavioral pain scale156. It is recommended 
to use the intravenous infusion of narcotic analgesics as the 
primary treatment for pain control in ICU157. Fentanyl, hy-
dromorphone, morphine, remifentanil, and methadone can 
be used as narcotic analgesics, and they should be applied 
to each patient individually according to pharmacokinetic 
and pharmacodynamic properties of each drug. Currently, 
methadone is not available in South Korea. The use of meperi-
dine should be avoided because of risks including neurologic 
toxicity158. Non-narcotic analgesics (IV acetaminophen, a 
cyclooxygenase inhibitor, and ketamine) can be administered 
concomitantly to reduce side effects by narcotic analgesics. 
For neuropathic pain, the drugs including gabapentin or car-
bamazepine should be orally administered in combination 
with narcotic analgesics. In addition to IV analgesics admin-
istration, thoracic epidural analgesia is also effective for rib 
fracture or abdominal aortic aneurysm surgery154.
Since the pathophysiology and definitive treatment of delir-
ium are not evaluated enough, further studies are still needed. 
According to the studies published so far, however, risk factors 
that may cause the occurrence of delirium include the seri-
ousness of disease at ICU admission, history of alcohol use, 
and excessive physical binding in ICU159. Delirium is closely 
related to increase of various complications such as increased 
length of stay in ICU or hospital admission, and increased 
mortality as well as deterioration of cognitive functions159,160. 
Therefore, it is recommended to evaluate the occurrence of 
delirium regularly. Confusion Assessment Methods for the 
ICU (CAM-ICU) or Intensive Care Delirium Screening Check-
list (ICDSC) can be the most reliable evaluation methods to 
evaluate delirium in ICU161,162. In delirium, prevention rather 
than treatment is more important. For the non-pharmacolog-
ical method, early rehabilitation treatment such as early am-
bulation is recommended163. If delirium occurs, conservative 
treatment should be conducted, and excessive use of sedative 
should be avoided. There is no clear evidence on atypical 
antipsychotics such as haloperidol. The prevention and treat-
ment of sedation, analgesia, and delirium in ICU cannot make 
individually, but should be connected each other. Also, to give 
adequate analgesics and sedatives to all mechanically venti-
lated patients including ARDS, a variety of multidisciplinary 
approaches and studies are required.
12. Early tracheostomy in mechanically ventilated 
patients
1) Recommendation
- We suggest early tracheostomy in patients who receive 
mechanical ventilation can be performed only in limited cases 
(grade 2A). 
2) Key points
- Early tracheostomy may decrease the hospital length of 
stay in limited patients and the use of sedative drugs.
- Early tracheostomy may not lower ICU mortality and the 
incidence of ventilator-associated pneumonia (VAP), or short-
en the duration of mechanical ventilation.
The definition of early tracheostomy varies among studies. 
Generally, the operation conducted before 7–10 days from in-
tra-tracheal intubation can be defined as “early tracheostomy.” 
Otherwise, “late” or “delayed” tracheostomy means that the 
operation was performed after 10 days of intubation. Three 
randomized control studies164-166, two meta-analyses167,168, and 
one review article169 were examined. According to the results 
of recently published large-scale randomized control stud-
ies, all studies by Terragni et al.164, Trouillet et al.165, and Young 
et al.166 which were large-scale randomized control studies, 
did not show a mortality reduction in the early tracheostomy 
group. Meta-analyses studies by Wang et al.167 and Huang 
et al.168 did not also show an effect on short- and long-term 
mortality. The randomized control study by Terragni et al.164, 
revealed the number of ventilator-free days was significantly 
greater in the early tracheostomy group (11 days vs. 6 days, 
p=0.02), but the other randomized control studies and meta-
analyses could not prove the statistical significance. All three 
randomized control studies and two meta-analyses164-168 
showed that early tracheostomy did not shorten ICU length of 
stay and hospital length of stay. Only Terragni et al.164 showed 
that the number of ICU discharges was significantly higher in 
the early tracheostomy group (48% vs. 39%, p=0.03), but the 
duration of hospital stay was not different. However, the pa-
tients with a chronic pulmonary disorder or respiratory tract 
infection were all excluded in that study, and those were only 
a small proportion of mechanically ventilated patients. Thus, 
interpretation of the result requires special caution in clinical 
practice. 
In the study by Terragni et al.164, the early tracheostomy 
group showed a lower incidence of VAP, but the study could 
not prove the statistical significance (14% vs. 21%, p=0.07). In 
meta-analyses, early tracheostomy had no effect on the reduc-
tion VAP incidence. In the study by Trouillet et al.165, reported 
early tracheostomy was associated with less need for intrave-
nous sedation; the use of midazolam (mean difference, –0.31 
mg/kg/day; 95% CI, –0.53 to –0.09 mg/kg/day), propofol (mean 
difference, –2.87 mg/kg/day; 95% CI, –4.76 to –0.98 mg/kg/
day), and sufentanil (mean difference, –0.48 µg/kg/day; 95% 
CI, –0.77 to –0.19 µg/kg/day). Young et al.166 proved days de-
manding any sedative was significantly lower in the 30-day 
survivor subgroup analysis (5 days vs. 8 days; median differ-
ence, 2.4; 95% CI, 1.6–3.6 days; p<0.001).
In the recent meta-analyses and large-scale randomized 
control studies, early tracheostomy could not lower the mor-
tality and incidence of VAP. Also, early tracheostomy did not 
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significantly affect the duration of ICU stay and hospital stay. 
However, because these studies have a limitation on the sub-
jects, and the results cannot be uniformly applied to all critical 
patients. Generally, tracheostomy should be considered in the 
following cases: (1) patients at risk of airway obstruction, (2) 
patients with recurrent weaning failure, (3) patients who need 
airway hygiene or toileting due to a bed-ridden or prolonged 
unconscious status. Thus, the optimal time for performing 
a tracheostomy should be determined after considering the 
clinical situation of patients, preference of patients, bronchial 
secretions, causes of respiratory failure, benefits or disadvan-
tages of tracheostomy, and others. The basis for performing an 
early tracheostomy in patients who receive mechanical venti-
lation has not yet been established.
Conclusion
The research network initiated by the National Institutes of 
Health in the United States was recently dispersed while left 
decades of therapeutic trials for ARDS. Nevertheless, most 
of their results were negative, recent positive clinical trials of 
neuromuscular blockage and prone positioning suggested 
hopeful directions to make an advance in this uncontrollable 
clinical syndrome, in addition to the traditional lung protec-
tive strategy including low tidal volume ventilation, high 
PEEP, or recruitment maneuver. Moreover, ECMO, a revisited 
technique described more than decades ago, might be a still 
optional choice, however, systemic steroids and iNO would be 
less or no effective treatment based on up-to-date evidence. 
Besides ARDS, low tidal volume ventilation and light sedation 
should be considered in most of the patients who receive me-
chanical ventilation in the ICU and early tracheostomy could 
also be attempted in limited patients. Undoubtedly, over the 
next decade, ambitious research like the “ECMO to rescue 
Lung injury in severe ARDS (EOLIA)” trial would be conduct-
ed, and their results will contribute to revising this brand-new 
clinical practice guideline for mechanically ventilated patients 
with or without ARDS.
Summary of Recommendations
1. We recommend low tidal volume ventilation can be ap-
plied to patients with ARDS to reduce mortality (grade 1A).
The tidal volume should be maintained less than 6 mL/kg of 
predicted body weight in patients with ARDS.
The plateau pressure should be maintained less than 30 
cmH2O in patients with ARDS.
2. We suggest high PEEP can be applied to patients with 
ARDS, who have PaO2/FIO2 ≤200 mm Hg to reduce mortality 
(grade 2B). 
The application of high PEEP does not increase the risk of 
barotrauma.
If high PEEP is applied, PaO2/FIO2 at day 1 and three can be 
improved compared to the application of low PEEP group.
3. We recommend prone position can be applied to patients 
with moderate or above ARDS to reduce mortality if it is not 
contraindicated (grade 1B). 
Prone position should be applied when there is no improve-
ment of oxygenation at early stage of mechanical ventilation.
Prone position is recommended at least for 10 hours.
Lung protective strategy should also be applied during 
prone positioning.
4. We suggest ECMO as a rescue therapy in patients with 
ARDS without improvement of hypoxia by lung protective 
strategy (grade 2C). 
5. We suggest recruitment maneuver can be applied to pa-
tients with ARDS to reduce mortality (grade 2B). 
Recruitment maneuver has an effect on improving hypoxia, 
without increasing the risk of barotrauma.
6. The use of systemic steroids cannot reduce mortality in 
patients with ARDS (grade 2B).
In the case of a low dose of systemic steroid is used in the 
early stage, it may improve hypoxemia and reduce the period 
of mechanical ventilation, the length of ICU stay, and mortal-
ity.
7. We suggest neuromuscular blockade for 48 hours after 
starting mechanical ventilation in patients with ARDS (grade 
2B). 
The use of neuromuscular blockage in patients with ARDS 
has an effect on improvement of hypoxemia for first 48 hours. 
The use of neuromuscular blockage can reduce barotrauma 
such as pneumothorax in patients with ARDS.
8. The use of HFOV should not be recommended as a stan-
dard treatment method in adult patients with ARDS (grade 
1B).
HFOV does not improve survival in patients with ARDS.
HFOV may cause side effects such as barotrauma or low 
blood pressure.
9. The use of iNO should not be recommended as a stan-
dard treatment method in adult and child patients with ARDS 
(grade 1A). 
The use of iNO in patients with ARDS may increase the risk 
of renal injury in adults.
10. We recommend low tidal volume ventilation can be ap-
plied in patients who require mechanical ventilation for dis-
eases other than ARDS (grade 1B). To lower the incidence of 
pulmonary complications including ARDS in intraoperative 
patients, lung protective ventilation strategy may be applied 
during the operation (grade 2B). 
11. We recommend light sedation should be conducted in 
critically ill patients who receive mechanical ventilation in-
cluding ARDS (grade 1B). 
We suggest pain should regularly be evaluated in critically ill 
patients who receive mechanical ventilation in ICU.
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It is required to have a proper prevention for the occurrence 
of delirium caused by the absence of appropriate analgesia 
and sedation or other physical diseases.
12. We suggest early tracheostomy in patients who receive 
mechanical ventilation can be performed only in limited cases 
(grade 2A). 
Early tracheostomy may decrease the hospital length of stay 
in limited patients.
Early tracheostomy may decrease the use of sedative drugs.
Early tracheostomy may not lower ICU mortality and the 
incidence of ventilator-associated pneumonia, or shorten the 
duration of mechanical ventilation.
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